Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atacicept Long-Term Extension in SLE
NCT02070978Phase 2Terminated
- Sponsor
- EMD Serono
- Start
- Jul 2014
- Primary completion
- Apr 2016
- Modality
- Fc-Fusion Proteins
- Countries
- 17
01
Overview
Phase 2, double-blind trial of atacicept in systemic lupus erythematosus (SLE) (3 arms), sponsored by EMD Serono. Primary endpoints: Serious Adverse Events up to 143.7 weeks and Discontinuation due to Adverse Events up to 167.7 weeks. Started Jul 2014; status: terminated.
02
Drugs
atacicept
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02070978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02070978.